UK Community Advisory Board (UK-CAB)
UK-CAB 32 – Meeting report

UK-CAB 32 – Meeting report

Advocacy training day

Confidence building workshop Skill-building session NHS structures in the UK Getting other advocates involved What next - active involvement

UK-CAB 31 – Meeting report

UK-CAB 31 – Meeting report

Ageing and HIV

UKCHIC Proposed Ageing Study Ageing with HIV: Project Overview Will we ever get to be old and wise? BHIVA Conference overview Pre-meeting for Abbott Community Meeting update from Abbott Community Q & A with Abbott HIV and Ageing interactive session

UK-CAB 30 – Meeting Full Report

UK-CAB 30 – Meeting Full Report

Testing

BHIVA Routine Monitoring Guidelines HIV Treatment Advocacy Overview Definitions of Advocacy Denver Principles History of Advocacy Film highlights Advocacy Training in Practice Pre-Meeting for Bristol-Myers Squibb Bristol-Myers Squibb Community Meeting, Q&A Company meeting: BMS IAS Conference Feedback

UK-CAB 30 – Meeting Summary Report

UK-CAB 30 – Meeting Summary Report

Testing

BHIVA Routine Monitoring Guidelines HIV Treatment Advocacy Overview Definitions of Advocacy Denver Principles History of Advocacy Film highlights Advocacy Training in Practice Pre-Meeting for Bristol-Myers Squibb Bristol-Myers Squibb Community Meeting, Q&A Company meeting: BMS IAS Conference Feedback

UK-CAB 29 – Meeting report

UK-CAB 29 – Meeting report

Resistance Revisited

Introducing the HIV Vaccine Advisory Board-Ken Legg, MRC and St Marys Hospital Resistance Explored Professor Deenan Pillay Company meeting: GSK abacavir, pipeline drugs and merger

UK-CAB 28 – Meeting report

UK-CAB 28 – Meeting report

Late Presenters

BMS/Gilead patient education programme Training and presentations: Immunology Company meeting:Tibotec Etravirine overview including comment on drug interaction, Darunavir European license extended to all treatment-experienced Rilpivirine (TMC-278) Next generation first-line NNRTI and pipeline HIV plus HCV and TB

UK-CAB 27 – Meeting report

UK-CAB 27 – Meeting report

Transition from Paediatric Care to Adult Services

Training and presentations: Mexico Feedback. BHIVA Education Scientific Committee Feedback. BHIVHA/CHIVHA Feedback. Update on the HCQ and PIVOT trials. Transitional Care from Paediatric to Adult Services: A Clinical Care Perspective. Young People and HIV: A Social Support Perspective

UK-CAB 26 – Meeting Report

UK-CAB 26 – Meeting Report

TB and HIV — reporting adverse drug reactions — Theratechnologies

Training and presentations: TB and HIV - Yellow Card scheme for reporting adverse drug reactions - feedback from UNGASS, New York and Resistance Workshop, Sitges. Company meeting: Theratechnologie

UK-CAB 25 – Meeting Report

UK-CAB 25 – Meeting Report

Reading study results — D:A:D study — BHIVA treatment guidelines — GSK

Training and presentations: Interpreting risk and confidence in study results - D:A:D study: abacavir, ddI and risk of heart attack - conference feedback from CROI 2008. Company meeting: GlaxoSmithKline - abacavir and data on risk of heart attack, drugs in development. Community consultation: BHIVA draft treatment guidelines.

UK-CAB 24 – Meeting report

UK-CAB 24 – Meeting report

BHIVA 2007 clinical audit — microbicides — PEPSE — PrEP — Pfizer

Training and presentations: BHIVA 2007 clinical audit: treatment of naïve patients - campaigning for microbicides - promoting PEPSE: role of the HIV treatment advocate - PrEP (pre-exposure prophylaxis). Company meeting: Pfizer - the drug development process.